lactobacillus reuteri (SB-121) / Scioto Biosci, Genome & Company - LARVOL DELTA

Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder. (PubMed, Sci Rep) - P1 | "SB-121 was safe and well tolerated. SB-121-associated directional improvements in adaptive behavior measured by Vineland-3 and social preference as measured with eye tracking were noted.Trial registration: clinicaltrials.gov Identifier: NCT04944901."

Journal • P1 data • Autism Spectrum Disorder • CNS Disorders • Developmental Disorders • Genetic Disorders • Psychiatry

Scioto Biosciences Announces Publication of Phase 1b Study in Autism (Businesswire) - P1b | N=15 | NCT04944901 | Sponsor: Scioto Biosciences, Inc. | "Scioto Biosciences...today announced the publication of results from a Phase 1b study of their lead product SB-121 in patients with Autistic Spectrum Disorder (ASD)....'We are very pleased to have this study accepted for publication. It is an exciting result that certainly warrants further investigation in a larger Phase II study.'"

P1 data • Autism Spectrum Disorder • Developmental Disorders

SBI-SB121-20-01: 28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder (clinicaltrials.gov) - P1 | N=15 | Completed | Sponsor: Scioto Biosciences, Inc. | Recruiting ➔ Completed

Trial completion • CRP • TNFA

SBI-SB121-20-01: 28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder (clinicaltrials.gov) - P1; N=16; Recruiting; Sponsor: Scioto Biosciences, Inc.; Trial completion date: Nov 2021 ➔ Apr 2022; Trial primary completion date: Nov 2021 ➔ Apr 2022

Clinical • Trial completion date • Trial primary completion date • CRP • TNFA

SBI-SB121-20-01: 28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder (clinicaltrials.gov) - P1; N=16; Recruiting; Sponsor: Scioto Biosciences, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • CRP • TNFA

28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder (clinicaltrials.gov) - P1; N=16; Not yet recruiting; Sponsor: Scioto Biosciences, Inc.

Clinical • New P1 trial • CRP • TNFA

Long-term molecular surveillance provides clues on a cattle origin for Mycobacterium bovis in Portugal. (PubMed, Sci Rep) - "Common genotypic profiles within and among livestock and wildlife in the same spatiotemporal context highlighted epidemiological links across hosts and regions, as for example the SB0119-M205 genotype shared by cattle in Beja district or SB0121-M34 shared by the three hosts in Castelo Branco and Beja districts. The second cluster was predominant in the 2012-2016 period, holding the county Rosmaninhal at the centre, in Castelo Branco district, for which wild boar contributed the most in relative risk. These results provide novel quantitative insights beyond empirical perceptions, that may inform adaptive TB control choices in different regions."

Journal • Infectious Disease • Respiratory Diseases • Tuberculosis

The Xpert MTB/RIF Ultra assay detects Mycobacterium tuberculosis complex DNA in white rhinoceros (Ceratotherium simum) and African elephants (Loxodonta africana). (PubMed, Sci Rep) - "In this study, the limit of detection (LOD) of M. tuberculosis H37Rv in all spiked animal samples were 2 CFU/ml compared to 15.6 CFU/ml for humans, while the LOD for M. bovis SB0121 was 30 CFU/ml compared to 143.4 CFU/ml for M. bovis BCG in humans...In conclusion, the Ultra assay appears to be a sensitive and rapid diagnostic test for the detection of MTBC DNA from tissue and respiratory samples collected from African elephants and rhinoceros. Furthermore, the Ultra assay could provide a new tool for the detection of MTBC in various sample types from other wildlife species."

Journal • Preclinical • Infectious Disease • Tuberculosis